Ionis Pharmaceuticals Announces Public Offering of Common Stock

Details

announced a public offering of common stock under its effective shelf registration statement on Form S-3. The company aims to use the proceeds from this offering to continue investing in its commercial readiness efforts, innovative pipeline, and technology. Ionis Pharmaceuticals currently has five marketed medicines and a rich pipeline in various stages of development, focusing on RNA therapies for serious diseases.

Items reported

About Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.